Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Medshine Discovery Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed across 4 distinct examiners and 3 distinct art units, indicating a broad spread of current examination assignments relative to the pending docket.
KOSAR, ANDREW D is the busiest examiner, with 1 pending matter. Since the pending matters are associated with several examiner and art-unit contexts, counsel should organize the docket by prosecution issue and assignment rather than treat it as one consolidated examination. A shared technical theme may support consistency, but each response should remain grounded in its own record.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 2 (50%) |
| §112 only | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSAR, ANDREW D | 1 | 41.9% | +31.9% |
| LEE, WILLIAM Y | 1 | 48.0% | +34.1% |
| LEESER, ERICH A | 1 | 81.9% | +13.3% |
| DEKARSKE, MADELINE MCGUIRE | 1 | 20.0% | +50.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18682091 | DEUTERATED NUCLEOSIDE COMPOUNDS AND USE THEREOF | LEESER, ERICH A | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18730769 | CRYSTAL FORM OF ALLYL-CONTAINING METHYLPYRIDOPYRIMIDINE COMPOUND | KOSAR, ANDREW D | — |
| 18286326 | BICYCLIC SUBSTITUTED AROMATIC CARBOXYLIC ACID COMPOUNDS | DEKARSKE, MADELINE MCGUIRE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18730769 | CRYSTAL FORM OF ALLYL-CONTAINING METHYLPYRIDOPYRIMIDINE COMPOUND | KOSAR, ANDREW D | — |
| 18703171 | PYRROLOPYRAZOLE SPIRO COMPOUND | LEE, WILLIAM Y | — |
| 18682091 | DEUTERATED NUCLEOSIDE COMPOUNDS AND USE THEREOF | LEESER, ERICH A | — |
| 18286326 | BICYCLIC SUBSTITUTED AROMATIC CARBOXYLIC ACID COMPOUNDS | DEKARSKE, MADELINE MCGUIRE | — |
| Art Unit | Apps |
|---|---|
| 1622 | 2 |
| 1625 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18730769 | CRYSTAL FORM OF ALLYL-CONTAINING METHYLPYRIDOPYRIMIDINE COMPOUND | KOSAR, ANDREW D | 1625 | §101§102§112 | Non-Final OA | — | Pending | Jul 20, 2024 |
| 18703171 | PYRROLOPYRAZOLE SPIRO COMPOUND | LEE, WILLIAM Y | 1623 | §112 | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18682091 | DEUTERATED NUCLEOSIDE COMPOUNDS AND USE THEREOF | LEESER, ERICH A | 1622 | §103 | Non-Final OA | — | Pending | Feb 07, 2024 |
| 18286326 | BICYCLIC SUBSTITUTED AROMATIC CARBOXYLIC ACID COMPOUNDS | DEKARSKE, MADELINE MCGUIRE | 1622 | §103 | Non-Final OA | — | Pending | Oct 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMedshine Discovery Inc. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Andrew D Kosar has the most, with 1 of Medshine Discovery Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
